This “Insomnia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Insomnia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Insomnia Understanding
Insomnia is a sleep disorder that affects as many as 35% of adults. It is marked by problems getting to sleep, staying asleep through the night, and sleeping as long as you would like into the morning. It can have serious effects, leading to excessive daytime sleepiness, a higher risk of auto accidents, and widespread health effects from sleep deprivation. Common causes of insomnia include stress, an irregular sleep schedule, poor sleeping habits, mental health disorders like anxiety and depression, physical illnesses and pain, medications, neurological problems, and specific sleep disorders. For many people, a combination of these factors can initiate and exacerbate insomnia. There are numerous potential causes of insomnia, and in many cases, multiple factors can be involved. Poor sleep can also trigger or worsen other health conditions, creating a complex chain of cause-and-effect for insomnia. On a holistic level, insomnia is believed to be caused by a state of hyperarousal2 that disrupts falling asleep or staying asleep. Hyperarousal can be both mental and physical, and it can be triggered by a range of circumstances and health issues.
"Insomnia - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Insomnia pipeline landscape is provided which includes the disease overview and Insomnia treatment guidelines. The assessment part of the report embraces, in depth Insomnia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Insomnia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Insomnia R&D. The therapies under development are focused on novel approaches to treat/improve Insomnia.
This segment of the Insomnia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Daridorexant is a dual orexin receptor antagonist (DORA) designed and developed for the treatment of insomnia. Daridorexant reduces overactive wakefulness associated with insomnia by blocking the activity of orexin. Idorsia's research team has designed daridorexant to have a rapid onset of effect and a duration of action sufficient to cover the night but short enough to avoid any negative next-morning residual activity at optimally effective doses. The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for review of Idorsia's investigational dual orexin receptor antagonist, daridorexant, for the treatment of adult patients with insomnia.
TS 142 is dual orexin 1/2 receptor antagonist (DORA), being developed by Taisho Pharmaceutical, for the treatment of insomnia and sleep apnoea syndrome.
This segment of the report provides insights about the different Insomnia drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the therapies for Insomnia. The companies which have their Insomnia drug candidates in the most advanced stage, i.e. preregistration include, Idorsia Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Insomnia therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Insomnia drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2-4 business days.
Geography Covered
- Global coverage
Insomnia Understanding
Insomnia: Overview
Insomnia is a sleep disorder that affects as many as 35% of adults. It is marked by problems getting to sleep, staying asleep through the night, and sleeping as long as you would like into the morning. It can have serious effects, leading to excessive daytime sleepiness, a higher risk of auto accidents, and widespread health effects from sleep deprivation. Common causes of insomnia include stress, an irregular sleep schedule, poor sleeping habits, mental health disorders like anxiety and depression, physical illnesses and pain, medications, neurological problems, and specific sleep disorders. For many people, a combination of these factors can initiate and exacerbate insomnia. There are numerous potential causes of insomnia, and in many cases, multiple factors can be involved. Poor sleep can also trigger or worsen other health conditions, creating a complex chain of cause-and-effect for insomnia. On a holistic level, insomnia is believed to be caused by a state of hyperarousal2 that disrupts falling asleep or staying asleep. Hyperarousal can be both mental and physical, and it can be triggered by a range of circumstances and health issues.
"Insomnia - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Insomnia pipeline landscape is provided which includes the disease overview and Insomnia treatment guidelines. The assessment part of the report embraces, in depth Insomnia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Insomnia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Insomnia R&D. The therapies under development are focused on novel approaches to treat/improve Insomnia.
Insomnia Emerging Drugs Chapters
This segment of the Insomnia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Insomnia Emerging Drugs
Daridorexant: Idorsia Pharmaceuticals
Daridorexant is a dual orexin receptor antagonist (DORA) designed and developed for the treatment of insomnia. Daridorexant reduces overactive wakefulness associated with insomnia by blocking the activity of orexin. Idorsia's research team has designed daridorexant to have a rapid onset of effect and a duration of action sufficient to cover the night but short enough to avoid any negative next-morning residual activity at optimally effective doses. The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for review of Idorsia's investigational dual orexin receptor antagonist, daridorexant, for the treatment of adult patients with insomnia.
TS-142: Taisho Pharmaceutical
TS 142 is dual orexin 1/2 receptor antagonist (DORA), being developed by Taisho Pharmaceutical, for the treatment of insomnia and sleep apnoea syndrome.
Insomnia: Therapeutic Assessment
This segment of the report provides insights about the different Insomnia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Insomnia
There are approx. 20+ key companies which are developing the therapies for Insomnia. The companies which have their Insomnia drug candidates in the most advanced stage, i.e. preregistration include, Idorsia Pharmaceuticals.
Phases
This report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Insomnia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Insomnia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Insomnia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Insomnia drugs.
Insomnia Report Insights
- Insomnia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Insomnia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Insomnia drugs?
- How many Insomnia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Insomnia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Insomnia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Insomnia and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Taisho Pharmaceutical
- Sunshine Lake Pharma
- Idorsia Pharmaceuticals
- Intra-Cellular Therapies
- Biolab Sanus Farmaceutica
- Sequential Medicine Ltd
- Janssen Research & Development
- Imbrium Therapeutics
- Evotec SE
- Ferrer
- Click Therapeutics
- IntelGenx
- LINNET BIOPHARMACEUTICALS INC.
- Somnus Therapeutics
- Neurim Pharmaceuticals
- Druggability Technologies
- Overseas Pharmaceuticals
- Rapid Therapeutic Science Laboratories
Key Products
- Daridorexant
- TS 142
- HEC 83518
- Lumateperone
- Zolpidem
- SM-1
- JNJ-42847922
- V117957
- IMB-115
- EVT 201
- Lorediplon
- Neu-P11
- CY 18
- DRGT 73
- CT-141
- INT0020
- SKP-1041
This product will be delivered within 2-4 business days.
Table of Contents
IntroductionExecutive Summary
Insomnia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Insomnia - Analytical Perspective
Late Stage Products (Preregistration)
- Comparative Analysis
Daridorexant: Idorsia Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
TS 142: Taisho Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
HEC 83518: Sunshine Lake Pharma
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
CY 18: Overseas Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Insomnia Key Companies
Insomnia Key Products
Insomnia- Unmet Needs
Insomnia- Market Drivers and Barriers
Insomnia- Future Perspectives and Conclusion
Insomnia Analyst Views
Insomnia Key Companies
AppendixList of Tables
Table 1 Total Products for Insomnia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Insomnia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Taisho Pharmaceutical
- Sunshine Lake Pharma
- Idorsia Pharmaceuticals
- Intra-Cellular Therapies
- Biolab Sanus Farmaceutica
- Sequential Medicine Ltd
- Janssen Research & Development
- Imbrium Therapeutics
- Evotec SE
- Ferrer
- Click Therapeutics
- IntelGenx
- LINNET BIOPHARMACEUTICALS INC.
- Somnus Therapeutics
- Neurim Pharmaceuticals
- Druggability Technologies
- Overseas Pharmaceuticals
- Rapid Therapeutic Science Laboratories
